UPDATED Apr 25, 2024
All the companies in the healthcare sector, including healthcare provider and equipment, healthcare tech, pharmaceuticals, biotech and life sciences.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
LLY | US$724.87 | -2.8% | 85.7% | US$652.9b | US$813.32 | PE124.6x | E27.2% | 0.7% | Pharmaceuticals & Biotech | ||
UNH | US$493.86 | 0.1% | 0.7% | US$454.4b | US$567.36 | PE29.6x | E19.7% | 1.5% | Healthcare | ||
JNJ | US$146.82 | 0.7% | -9.9% | US$353.8b | US$173.60 | PE18.5x | E5.1% | 3.4% | Pharmaceuticals & Biotech | ||
MRK | US$130.72 | 4.4% | 13.5% | US$331.1b | US$138.74 | PE143.6x | E26.3% | 2.4% | Pharmaceuticals & Biotech | ||
ABBV | US$167.29 | 1.6% | 12.4% | US$296.2b | US$184.14 | PE61.5x | E23.4% | 3.7% | Pharmaceuticals & Biotech | ||
AZN | UK£120.26 | 10.2% | 1.9% | UK£186.4b | UK£128.74 | PE36.8x | E16.5% | 1.9% | Pharmaceuticals & Biotech | ||
TMO | US$571.73 | 5.6% | 5.3% | US$218.2b | US$618.21 | PE36.2x | E12.0% | 0.3% | Pharmaceuticals & Biotech | ||
ABT | US$106.86 | 1.5% | -2.4% | US$185.4b | US$126.33 | PE33.1x | E11.3% | 2.1% | Healthcare | ||
DHR | US$245.80 | 4.0% | 6.2% | US$182.1b | US$269.22 | PE44.7x | E13.5% | 0.4% | Pharmaceuticals & Biotech | ||
AMGN | US$269.38 | 2.5% | 12.1% | US$144.5b | US$300.27 | PE21.5x | E8.9% | 3.3% | Pharmaceuticals & Biotech | ||
PFE | US$25.26 | -0.5% | -34.8% | US$143.0b | US$31.62 | PE67x | E22.3% | 6.7% | Pharmaceuticals & Biotech | ||
ISRG | US$373.12 | 0.1% | 26.1% | US$132.3b | US$420.28 | PE66.6x | E11.5% | n/a | Healthcare | ||
SYK | US$337.15 | 3.0% | 13.1% | US$128.2b | US$365.69 | PE40.5x | E12.7% | 0.9% | Healthcare | ||
ELV | US$539.68 | 2.8% | 16.0% | US$125.4b | US$599.48 | PE20.1x | E12.5% | 1.2% | Healthcare | ||
BSX | US$73.26 | 8.7% | 40.8% | US$107.7b | US$79.72 | PE61x | E18.1% | n/a | Healthcare | ||
MDT | US$79.25 | 0.08% | -13.3% | US$105.2b | US$94.75 | PE25x | E10.3% | 3.5% | Healthcare | ||
VRTX | US$397.70 | 1.1% | 17.2% | US$102.8b | US$460.34 | PE28.4x | E11.5% | n/a | Pharmaceuticals & Biotech | ||
CI | US$354.51 | 1.6% | 41.6% | US$100.6b | US$381.44 | PE19.5x | E9.6% | 1.6% | Healthcare | ||
BMY | US$48.86 | 2.1% | -28.2% | US$99.3b | US$56.20 | PE12.3x | E9.9% | 4.9% | Pharmaceuticals & Biotech | ||
REGN | US$890.68 | -0.4% | 12.4% | US$95.7b | US$1,036.08 | PE24.2x | E10.9% | n/a | Pharmaceuticals & Biotech | ||
CSL | AU$278.45 | 2.6% | -8.4% | AU$134.6b | AU$306.71 | PE35.4x | E14.7% | 1.3% | Pharmaceuticals & Biotech | ||
CVS | US$67.33 | -3.0% | -7.8% | US$84.9b | US$88.42 | PE10.2x | E7.1% | 4.0% | Healthcare | ||
GSK | UK£16.41 | 3.6% | 14.2% | UK£67.0b | UK£20.06 | PE13.6x | E9.3% | 3.5% | Pharmaceuticals & Biotech | ||
HCA | US$314.12 | 5.8% | 11.2% | US$83.1b | US$341.19 | PE15.8x | E6.4% | 0.8% | Healthcare |